EUVIMEDEUVIMED entdecken
Crossref

Phage Therapy in Lung Transplantation: Current Status and Future Possibilities

Saima Aslam iD

Clinical Infectious Diseases · 02.11.2023 · 77 (Supplement_5) · S416-S422

DOI: 10.1093/cid/ciad528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 02.11.2023. Verfasst von Saima Aslam. Beteiligte Einrichtung: Center for Innovative Phage Applications and Therapeutics, Division of Infectious Diseases and Global Public Health, University of California San Die…. Hauptthemen laut MEDLINE: Phage Therapy, Lung Transplantation, Lung Diseases, Bacteriophages. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation, American Society of Transplantation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with chronic lung disease and lung transplantation have high rates of colonization and infection from multidrug-resistant (MDR) organisms. This article summarizes the current state of knowledge regarding phage therapy in the setting of lung transplantation. Phage therapy has been used in several lung transplant candidates and recipients on a compassionate use basis targeting mostly MDR gram-negative infections and atypical mycobacterial infections with demonstrated clinical safety. Phage biodistribution given intravenously or via nebulization has not been extensively studied, though preliminary data are presented. Phage interacts with both the innate and adaptive immune system; current literature demonstrates the development of serum neutralization in some cases of phage therapy, although the clinical impact seems variable. A summary of current clinical trials involving patients with chronic lung disease is presented, though none are specifically targeting lung transplant candidates or recipients. In addition to treatment of active infections, a variety of clinical scenarios may benefit from phage therapy, and well-designed clinical trials involving this vulnerable patient population are needed: pre- or peritransplantation use of phage in the setting of MDR organism colonization may lead to waitlisting of candidates currently declined by many centers, along with potential reduction of waitlist mortality rates and posttransplant infections; phage may be used for biofilm-related bronchial stent infections; and, finally, there is a possibility that phage use can affect allograft function and chronic rejection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phage TherapyLung TransplantationLung DiseasesBacteriophagesHumansTissue DistributionDrug Resistance, Multiple, BacterialGram-Negative BacteriaAnti-Bacterial Agents

Stichwörter der Autor:innen

bacteriophagecystic fibrosislung transplantmultidrug-resistant organismsphage

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Center for Innovative Phage Applications and Therapeutics, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Saima Aslam

Förderung

  • Cystic Fibrosis Foundation
  • American Society of Transplantation

Zitieren

APA

Aslam, S. (2023). Phage Therapy in Lung Transplantation: Current Status and Future Possibilities. Clinical Infectious Diseases, 77(Supplement_5), S416-S422. https://doi.org/10.1093/cid/ciad528

Vancouver

Aslam S. Phage Therapy in Lung Transplantation: Current Status and Future Possibilities. Clinical Infectious Diseases. 2023;77(Supplement_5):S416-S422. doi:10.1093/cid/ciad528

BibTeX
@article{Aslam2023,
  author = {Aslam, Saima},
  title = {Phage Therapy in Lung Transplantation: Current Status and Future Possibilities},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {Supplement_5},
  pages = {S416--S422},
  doi = {10.1093/cid/ciad528}
}
Kostenlos starten →